Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11

AIM: To evaluate the long‐term cost‐effectiveness of once‐weekly semaglutide 1 mg versus insulin aspart in the UK. MATERIALS AND METHODS: Long‐term outcomes were projected over patients' lifetimes using the IQVIA CORE Diabetes Model (vers 9.0). SUSTAIN 11 was used to inform baseline cohort characteristics and treatment effects. Patients were modelled to receive once‐weekly semaglutide plus basal insulin for 3 years before intensifying to basal‐bolus insulin, compared with basal‐bolus insulin for lifetimes in the aspart arm. Costs were accounted from a healthcare payer perspective in the UK, expressed in 2021 pounds sterling (GBP). RESULTS: Once‐weekly semaglutide 1 mg was associated with improvements in quality‐adjusted life expectancy of 0.18 quality‐adjusted life years (QALYs) versus insulin aspart, due to a reduced incidence and delayed time to onset of diabetes‐related complications. Direct costs were estimated to be GBP 800 higher with semaglutide, with higher treatment costs partially offset by cost savings from avoidance of diabetes‐related complications. Once‐weekly semaglutide 1 mg was therefore associated with an incremental cost‐effectiveness ratio of GBP 4457 per QALY gained versus insulin aspart. CONCLUSIONS: Based on a willingness‐to‐pay threshold of GBP 20 000 per QALY gained, once‐weekly semaglutide 1 mg was projected to be highly cost‐effective versus insulin aspart for the treatment of type 2 diabetes in the UK.